AR037457A1 - Compuestos derivados de benzotiazol, su empleo, un procedimiento para prepararlos y medicamentos que los contienen - Google Patents
Compuestos derivados de benzotiazol, su empleo, un procedimiento para prepararlos y medicamentos que los contienenInfo
- Publication number
- AR037457A1 AR037457A1 ARP020104580A ARP020104580A AR037457A1 AR 037457 A1 AR037457 A1 AR 037457A1 AR P020104580 A ARP020104580 A AR P020104580A AR P020104580 A ARP020104580 A AR P020104580A AR 037457 A1 AR037457 A1 AR 037457A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- disease
- compounds
- general formula
- prepare
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 3
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- -1 opioids Chemical compound 0.000 abstract 2
- 208000011117 substance-related disease Diseases 0.000 abstract 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 abstract 1
- 108050000203 Adenosine receptors Proteins 0.000 abstract 1
- 102000009346 Adenosine receptors Human genes 0.000 abstract 1
- 101150051188 Adora2a gene Proteins 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 229940025084 amphetamine Drugs 0.000 abstract 1
- 229940125681 anticonvulsant agent Drugs 0.000 abstract 1
- 239000001961 anticonvulsive agent Substances 0.000 abstract 1
- 239000000164 antipsychotic agent Substances 0.000 abstract 1
- 229940005529 antipsychotics Drugs 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 229930003827 cannabinoid Natural products 0.000 abstract 1
- 239000003557 cannabinoid Substances 0.000 abstract 1
- 229940065144 cannabinoids Drugs 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 229940045200 cardioprotective agent Drugs 0.000 abstract 1
- 239000012659 cardioprotective agent Substances 0.000 abstract 1
- 229960003920 cocaine Drugs 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 229960004756 ethanol Drugs 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 229940035363 muscle relaxants Drugs 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 239000003158 myorelaxant agent Substances 0.000 abstract 1
- 230000004112 neuroprotection Effects 0.000 abstract 1
- 229960002715 nicotine Drugs 0.000 abstract 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229940005483 opioid analgesics Drugs 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 230000029058 respiratory gaseous exchange Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 229940125723 sedative agent Drugs 0.000 abstract 1
- 239000000932 sedative agent Substances 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01128338 | 2001-11-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR037457A1 true AR037457A1 (es) | 2004-11-10 |
Family
ID=8179392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020104580A AR037457A1 (es) | 2001-11-29 | 2002-11-28 | Compuestos derivados de benzotiazol, su empleo, un procedimiento para prepararlos y medicamentos que los contienen |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6624163B2 (https=) |
| EP (1) | EP1450797B1 (https=) |
| JP (1) | JP4146799B2 (https=) |
| KR (1) | KR100581704B1 (https=) |
| CN (1) | CN1304383C (https=) |
| AR (1) | AR037457A1 (https=) |
| AT (1) | ATE330603T1 (https=) |
| AU (1) | AU2002365506B2 (https=) |
| BR (1) | BR0214488A (https=) |
| CA (1) | CA2468311C (https=) |
| DE (1) | DE60212694T2 (https=) |
| ES (1) | ES2266608T3 (https=) |
| MX (1) | MXPA04005077A (https=) |
| PA (1) | PA8558701A1 (https=) |
| PE (1) | PE20030821A1 (https=) |
| PL (1) | PL373947A1 (https=) |
| RU (1) | RU2301232C2 (https=) |
| TW (1) | TW200408395A (https=) |
| UY (1) | UY27559A1 (https=) |
| WO (1) | WO2003045386A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007506654A (ja) | 2003-06-20 | 2007-03-22 | エフ．ホフマン−ラ ロシュ アーゲー | Ｃｂ１受容体逆作動物質としての２−アミノベンゾチアゾール類 |
| BRPI0414266A (pt) * | 2003-09-19 | 2006-11-07 | Hoffmann La Roche | derivados de tiazolopiridina como ligandos receptores da adenosina |
| TW200524887A (en) * | 2003-10-27 | 2005-08-01 | Lundbeck & Co As H | N-thiazol-2-yl-benzamide derivatives |
| CA2543707A1 (en) | 2003-10-31 | 2005-05-19 | Takeda Pharmaceutical Company Limited | Nitrogen-containing fused heterocyclic compounds |
| JP4740152B2 (ja) * | 2003-12-23 | 2011-08-03 | セロドス アクスイェ セルスカブ | 末梢性５−ｈｔ受容体の修飾因子 |
| EP1773795A1 (en) * | 2004-07-22 | 2007-04-18 | F.Hoffmann-La Roche Ag | Substituted benzothiazoles |
| CN1989139B (zh) * | 2004-07-22 | 2010-05-12 | 弗·哈夫曼-拉罗切有限公司 | 苯并噻唑衍生物 |
| US7910613B2 (en) | 2004-09-22 | 2011-03-22 | H. Lundbeck A/S | 2-acylaminothiazole derivatives |
| US7674912B2 (en) | 2005-04-25 | 2010-03-09 | H. Lundbeck A/S | Pro-drugs of N-thiazol-2-yl-benzamide derivatives |
| CN111205244B (zh) * | 2018-11-22 | 2023-08-18 | 上海科技大学 | 噻唑并环类化合物、其制备方法、中间体和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3374550D1 (en) | 1982-12-21 | 1987-12-23 | Johnsen Jorgensen Plastics Ltd | Dispensing container |
| FI91859C (fi) | 1987-06-17 | 1994-08-25 | Eisai Co Ltd | Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi |
| GB8717068D0 (en) * | 1987-07-20 | 1987-08-26 | Fujisawa Pharmaceutical Co | Nitric ester derivative |
| IL90337A0 (en) | 1988-05-24 | 1989-12-15 | Pfizer | Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents |
| DK0604657T3 (da) * | 1992-05-21 | 2000-04-17 | Otsuka Pharma Co Ltd | Phosphonsyrediesterderivat |
| AU8181701A (en) | 2000-06-21 | 2002-01-02 | Hoffmann La Roche | Benzothiazole derivatives |
-
2002
- 2002-11-15 US US10/295,500 patent/US6624163B2/en not_active Expired - Fee Related
- 2002-11-21 KR KR1020047007915A patent/KR100581704B1/ko not_active Expired - Fee Related
- 2002-11-21 AU AU2002365506A patent/AU2002365506B2/en not_active Ceased
- 2002-11-21 PL PL02373947A patent/PL373947A1/xx not_active Application Discontinuation
- 2002-11-21 RU RU2004119985/04A patent/RU2301232C2/ru not_active IP Right Cessation
- 2002-11-21 AT AT02790418T patent/ATE330603T1/de active
- 2002-11-21 ES ES02790418T patent/ES2266608T3/es not_active Expired - Lifetime
- 2002-11-21 MX MXPA04005077A patent/MXPA04005077A/es active IP Right Grant
- 2002-11-21 CA CA2468311A patent/CA2468311C/en not_active Expired - Fee Related
- 2002-11-21 WO PCT/EP2002/013046 patent/WO2003045386A1/en not_active Ceased
- 2002-11-21 JP JP2003546888A patent/JP4146799B2/ja not_active Expired - Fee Related
- 2002-11-21 EP EP02790418A patent/EP1450797B1/en not_active Expired - Lifetime
- 2002-11-21 BR BR0214488-3A patent/BR0214488A/pt not_active Application Discontinuation
- 2002-11-21 CN CNB028236939A patent/CN1304383C/zh not_active Expired - Fee Related
- 2002-11-21 DE DE60212694T patent/DE60212694T2/de not_active Expired - Lifetime
- 2002-11-25 TW TW091134237A patent/TW200408395A/zh unknown
- 2002-11-25 PE PE2002001131A patent/PE20030821A1/es not_active Application Discontinuation
- 2002-11-26 PA PA20028558701A patent/PA8558701A1/es unknown
- 2002-11-28 AR ARP020104580A patent/AR037457A1/es unknown
- 2002-11-28 UY UY27559A patent/UY27559A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003045386A1 (en) | 2003-06-05 |
| KR100581704B1 (ko) | 2006-05-22 |
| RU2004119985A (ru) | 2006-01-10 |
| PE20030821A1 (es) | 2003-10-04 |
| BR0214488A (pt) | 2004-10-19 |
| AU2002365506A1 (en) | 2003-06-10 |
| MXPA04005077A (es) | 2004-08-19 |
| US6624163B2 (en) | 2003-09-23 |
| CA2468311C (en) | 2011-03-15 |
| JP2005518363A (ja) | 2005-06-23 |
| US20030134855A1 (en) | 2003-07-17 |
| CA2468311A1 (en) | 2003-06-05 |
| PA8558701A1 (es) | 2003-09-05 |
| EP1450797B1 (en) | 2006-06-21 |
| AU2002365506B2 (en) | 2006-08-10 |
| TW200408395A (en) | 2004-06-01 |
| PL373947A1 (en) | 2005-09-19 |
| CN1304383C (zh) | 2007-03-14 |
| JP4146799B2 (ja) | 2008-09-10 |
| DE60212694D1 (de) | 2006-08-03 |
| DE60212694T2 (de) | 2007-06-28 |
| RU2301232C2 (ru) | 2007-06-20 |
| ATE330603T1 (de) | 2006-07-15 |
| KR20040062967A (ko) | 2004-07-09 |
| UY27559A1 (es) | 2003-05-30 |
| EP1450797A1 (en) | 2004-09-01 |
| CN1596112A (zh) | 2005-03-16 |
| ES2266608T3 (es) | 2007-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR037528A1 (es) | Derivados de piridona de benzotiazol | |
| BR0108611A (pt) | Moduladores de receptor de adenosina | |
| YU96502A (sh) | Derivati benzotiazola | |
| TW408102B (en) | Phenyl urea compounds and their use for the treatment of disease states medicated by the chemokine, Interleukin-8 (IL-8) | |
| DK0975595T3 (da) | Kokainanaloger | |
| AR037457A1 (es) | Compuestos derivados de benzotiazol, su empleo, un procedimiento para prepararlos y medicamentos que los contienen | |
| SG166125A1 (en) | New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimeræs disease | |
| AU2002359164A8 (en) | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 | |
| JP2005502680A5 (https=) | ||
| ES2634204T3 (es) | Composición farmacéutica que comprende derivados de piridona | |
| DE69333387D1 (de) | Pharmazeutische Zusammensetzungen enthaltend Norastemizol. | |
| SE0104331D0 (sv) | Novel compounds | |
| TW200507836A (en) | Therapeutic agents | |
| BRPI0409308A (pt) | derivados azabiciclo como antagonistas de receptores muscarìnicos, composição farmacêutica e processo para sua preparação | |
| AR037221A1 (es) | Compuestos derivados de piridina, uso de los mismos, un procedimiento para su preparacion y un medicamento que contiene uno o mas de dichos compuestos | |
| SG137850A1 (en) | Substituted n-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies | |
| SG140605A1 (en) | Benzothiazole derivatives | |
| AR037792A1 (es) | Compuestos derivados de benzotiazol, su uso, un procedimiento para su obtencion y medicamentos que los contienen | |
| Sano et al. | A fatal case of myocardial damage due to misuse of the “designer drug” MDMA | |
| UY29823A1 (es) | Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones | |
| AR049998A1 (es) | BENZOTIAZOLES SUSTITUIDOS COMO LIGANDOS DEL RECEPTOR DE ADENOSINA, PROCESO DE PREPARACIoN Y SU USO | |
| ES2181336T3 (es) | Espiro(piperidin-4,1'-pirrolo(3,4-c)pirrol). | |
| DE60142172D1 (de) | Benzopyranylheterocyclylderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen | |
| UY27574A1 (es) | Uso de ureas de benzotiazoles | |
| WO2006071603A3 (en) | Phosphodiesterase 4d in the ryanodine receptor complex protects against heart failure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |